Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib Maintenance Therapy for Locally Advanced Cervical Cancer
NCT03795272Phase 2Withdrawn
- Sponsor
- Nordic Society of Gynaecological Oncology Clinical Trial Unit
- Start
- Oct 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cervical Cancer (CC) comparing Rucaparib with Placebo (2 arms). Primary endpoint: Progression-Free Survival at 42 months. Planned start Oct 2019; status: withdrawn.
02
Drugs
rucaparib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03795272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795272.